Dynavax Announces HEPLISAV-B Post-Marketing Requirement Interim Report Completed

Author's Avatar
Dec 03, 2019
Article's Main Image

Similar rates of acute myocardial infarction between the two treatment arms at the interim analysis reinforces the view that HEPLISAV-B has the potential to be the leading hepatitis B vaccine for adults